Foghorn’s Phase I AML/MDS trial on FDA partial clinical hold due to subject death
No new subjects will be enrolled in the trial until the FDA lifts the partial clinical hold.
Hematological Disorders
Latest in
Hematological Disorders
AbbVie reports positive data from Phase II myelofibrosis therapy trial
The trial assessed the efficacy and tolerability of navitoclax alone or with ruxolitinib for myelofibrosis treatment.
Pipeline Moves: Terminations of fatty liver, blood cancer, ophthalmology clinical trials cause further study chances to nosedive
Bristol Myers Squibb, GT Biopharma, and Gemini Therapeutics terminate early-phase trials of their respective assets.
By
PhaseBio reports positive data from Phase IIb antibody trial in uncontrolled bleeding
Findings showed that bentracimab treatment substantially restored platelet function within five minutes of dosing.
Curis’ oral cancer therapy trial receives FDA partial clinical hold
The latest development comes after the company reported the death of a patient with R/R AML.
SDP Oncology doses first subject in Phase I/II leukaemia therapy trial
The open-label trial will have dose-escalation and dose-expansion portions to analyse DSP-5336 in AML or ALL patients.
CANbridge doses first subject in Phase Ib/II PNH treatment trial in China
The trial was initiated after the company obtained approval from China’s National Medical Products Administration.
Oryzon to commence Phase Ib acute myeloid leukaemia treatment trial
The Phase Ib FRIDA trial will assess iadademstat plus gilteritinib to treat R/R AML FLT3mut+ patients.